What is TB-500?
TB-500 is discussed for injury recovery because it is related to thymosin beta-4, a protein involved in cell movement and repair biology. The distinction between them matters before looking at any study: the full protein and a short fragment are different substances.
FDA's scientific review defines TB-500 as a seven-amino-acid fragment, Ac-LKKTETQ, with an added acetyl group. Full-length thymosin beta-4, often shortened to TB4, has 43 amino acids. The name on a product does not tell us that it matches the molecule tested in a paper. [1]
What do the fragment experiments show?
A 2003 wound study found improved healing in aged mice given TB4 or its seven-amino-acid segment LKKTETQ. That shorter segment lacked TB-500's acetyl modification. It is useful animal evidence, but it cannot establish that the modified fragment heals human tendon injuries. [2]
A 2024 study examined TB-500 metabolism in laboratory systems and rats, then tested the parent compound and its breakdown products in cultured fibroblasts. Only the metabolite Ac-LKKTE significantly improved wound closure compared with the control; TB-500 itself did not in that assay. That is a narrow finding, not proof of benefit in people or proof that the compound can never have an effect. [3]
TB4's relationship with actin, a protein involved in cell structure and movement, helps explain the research interest. It does not establish that a shorter, chemically modified fragment reproduces the full protein's actions. [1]
Has TB-500 been given to people in published research?
FDA's May 2026 review reported that it had found no human clinical studies of TB-500. A later September report described three dental nerve-injury cases treated with products identified as TB-500, BPC-157 and ARA-290, together with a steroid and local anesthetic. Sensation improved during follow-up and no treatment-related adverse events were reported. [1] [4]
Those cases add documented human experience. They do not isolate TB-500's contribution, confirm that it repaired nerves or establish safety. There was no control group, and natural recovery or the other treatments could explain the changes. The report also does not independently establish that every product sold under the TB-500 name has the same composition. [4]
What have trials of full-length TB4 found?
There is more human research on the full protein. The results include positive signals and missed primary outcomes. These studies test particular eye drops, gels or recombinant preparations in particular conditions.
Dry eye
A nine-patient randomized study found improvements in discomfort and corneal staining with RGN-259 eye drops. It was too small to settle the treatment question. A separate 72-person trial did not meet either primary endpoint, although several secondary measures favored treatment. [5] [6]
The larger ARISE-3 trial enrolled 700 people. Its sponsor reported that the primary outcomes were not met, while a secondary measure of grittiness improved. Results are posted in the registry. Positive secondary findings deserve further study, but they do not turn a negative primary result into a confirmed overall benefit. [7] [8]
A damaged corneal surface
SEER-1 studied neurotrophic keratopathy, an eye condition involving impaired corneal nerves and healing. Complete healing at four weeks occurred in six of ten people given RGN-259 and one of eight given placebo. The primary comparison did not reach statistical significance. The trial stopped early, and later secondary findings favored treatment. [9]
The larger SEER-2 registry was updated on November 5, 2026. It now lists completed status and 70 participants. No results were posted when checked on November 9. That is a study-status update, not an efficacy result. [10]
Recovery after a heart attack
A 2025 paper reports a randomized trial of recombinant human TB4 in 96 patients after treatment to reopen a blocked coronary artery. The overall comparison found no significant difference in the area of damaged heart muscle at 90 days. A subgroup receiving TB4 within eight hours had a smaller damaged area than placebo. The abstract does not establish whether that subgroup analysis was planned in advance, and it needs confirmation. This was full-length TB4, not TB-500. [11]
Chronic skin ulcers
A topical TB4 study in venous leg ulcers reported a possible healing signal at one concentration. The paper describes 73 randomized patients; the registry reports outcomes for 72. Across the three active doses combined, the registry reports complete healing in 12 of 55 people, compared with four of 17 receiving placebo. Those pooled figures do not resolve the narrower dose-specific suggestion. [12] [13]
A separate pressure-ulcer registry reports healing in eight of 54 people across active-dose groups and three of 18 receiving placebo. These small studies do not establish a general wound-healing benefit, and topical TB4 results cannot establish the effects of injected TB-500. [14]
What do we know about safety?
Safety findings also belong to the exact product and route studied. A randomized early study of intravenous recombinant TB4 in healthy volunteers reported mild to moderate adverse events, with no serious events or dose-limiting toxicity. That helps characterize the studied preparation over its short follow-up. It does not establish long-term safety or validate the TB-500 fragment. [15]
The small dental case report and laboratory work cannot supply a dependable risk estimate for TB-500. FDA's May review also described two reports about blended TB-500 and BPC-157, without safety assessments. Product identity, impurities, injection sterility and immune reactions remain relevant questions. [4] [1]
What changed in US compounding policy?
TB-500 is not an FDA-approved drug. The October 30, 2026 HHS notice describes a draft, non-binding enforcement-discretion policy. Its accompanying document covers TB-500 acetate for subcutaneous and intramuscular preparations under specified conditions, including patient-specific prescribing, ingredient testing and a single active ingredient. It does not establish effectiveness or final inclusion on the 503A bulks list. [1] [16] [17]
A clinician and dispensing pharmacy need to check the current rules for the actual product and treatment location. A research article, prescription, facility registration or policy announcement answers a different question from drug approval.
What about combining TB-500 with BPC-157?
A 2026 study compared four groups of rats after surgery to repair a cut Achilles tendon. The rats received a product called TB-500, BPC-157, both together or a control injection. After one month, tendons in the TB-500 group withstood a median force of 37 newtons before breaking, compared with 27 in controls. Adding BPC-157 showed no clear advantage over either peptide alone. [18]
Only four tendons per group underwent strength testing. The paper names the supplier and product code but gives no amino acid sequence to confirm which form of TB-500 the rats received. The researchers did not measure walking or long-term recovery. The three human dental cases also leave the question open because everyone received several treatments. Neither study tells us that combining the peptides improves tendon recovery in people. [18] [4]
Questions worth asking
- Is the proposed product full-length TB4 or the acetylated TB-500 fragment?
- Did the cited study test the same molecule, route and condition?
- Did its main outcome improve, or is the claim based on a secondary measure or subgroup?
- What human safety evidence and product-quality information apply?
- How would we judge benefit, watch for harm and decide when to stop?
The useful starting point is the actual molecule and the actual outcome. TB4 research deserves attention on its own terms. It cannot settle TB-500's benefits and risks by association.
Questions people ask
Are TB4 and TB-500 the same thing?
No. Full-length thymosin beta-4 has 43 amino acids. FDA defines TB-500 as a seven-amino-acid fragment with an acetyl modification. Findings for one do not establish the effects of the other.
Is there any published human experience with TB-500?
A September 2026 report describes three dental nerve-injury cases treated with products identified as TB-500 and other peptides, plus a steroid and local anesthetic. Improvement in those uncontrolled cases cannot establish which treatment helped or confirm TB-500 efficacy and safety.
Do the eye and heart trials prove TB-500 works?
No. Those trials studied full-length TB4 preparations. Several primary or overall results were negative or inconclusive, even where secondary outcomes or subgroups looked favorable. They do not establish a benefit for injected TB-500.
Is compounded TB-500 FDA-approved?
No. The October 2026 HHS document describes conditional enforcement discretion for specified TB-500 acetate injections. That is separate from FDA drug approval, final 503A listing and evidence that a treatment works.
Sources and further reading
The Achilles tendon and peptide combination evidence was checked November 10, 2026. Other clinical and regulatory sources were checked November 9, 2026. The cardiac, venous-ulcer and 2024 fragment papers remain abstract-level checks; unavailable methods and subgroup details are not assumed. SEER-2 has no posted results. This is an editorial evidence review, not a claim of medical review.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. TB-500 is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.